FCVB moderated poster award for Esmeralda Hemme
During the 2024 Frontiers in CardioVascular Biomedicine (FCVB) conference, which was held from April 12-14 in Amsterdam, Esmeralda Hemme from the BioTherapeutics division received the award for best moderated poster.
The FCVB conference, organized by Council on Basic Cardiovascular Science of the European Society of Cardiology, is the meeting where basic and translational cardiovascular biomedicine professionals discuss their work. During the moderated poster session, Esmeralda presented her study entitled “Leukemia inhibitory factor receptor inhibition reduces stenosis grade and total serum cholesterol levels in a mouse model for atherosclerosis”. In this study she showed that the cytokine Leukemia inhibitory factor (LIF) is expressed by mast cells in human atherosclerosis, whereas the LIF receptor is expressed by activated endothelial cells. Inhibition of the LIF receptor in Ldlr deficient mice limited stenosis grade, presumably by reducing circulating cholesterol levels and dampening of endothelial cell activation.
